3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
- N K Cheung
- B H Kushner
- S D Yeh
- S M Larson
Affiliations: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
- Published online on: June 1, 1998 https://doi.org/10.3892/ijo.12.6.1299
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.